On October 29, 2008 Debiopharm Group and the Japanese Cancer Association (JCA) will honour  two Japanese scientists with the JCA Mauvernay Award for their outstanding oncology research work in fundamental and clinical oncology.

The Award, funded by Debiopharm and organised by the JCA, aims to recognise cutting-edge oncology research in both the fundamental and the clinical aspects and to encourage Japanese researchers to make their work available to other parts of the world. Potential Candidates must be researchers and members of the JCA who have been recommended by the councillors of the JCA and who have achieved excellent results in the fields of either basic or clinical research in oncology. The JCA counts about 17,000 members, all from universities, governmental and private research organisations throughout Japan.

Each year, the Award Committee selects two nominees for the JCA-Mauvernay Award, one from fundamental cancer research and one from clinical cancer research.

Previous nominees:

2007 

• Professor Minoru Toyota, First Department of Internal Medicine, Sapporo Medical University,
• Professor Keiichi Nakayama, Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University

Japanese Scientists Receive JCA-Mauvernay Award 2007

2006

• Professor Hatakeyama, Institute for Genetic Medecine, Hokkaido University
• Professor Inazawa, Medical Research Institute, Tokyo Medical & Dental University

• - Dr Mitsudomi, Aichi Cancer Center Hospital
• - Dr Ishikawa, Graduate School of Biostudies, Kyoto University